LOS ANGELES and NIMES, France, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aanastra, Inc., a biotechnology company leveraging its proprietary targeted peptide delivery technology (PEP-NP™) to advance in vivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback